AstraZeneca Crestor Copromotion Decision Coming: Nexium Has 6% Share
Executive Summary
AstraZeneca expects to make a decision on whether to use a copromotion partner for the HMG-CoA reductase inhibitor Crestor (rosuvastatin) within "the next six to eight weeks," CFO Jonathan Symonds told the Goldman Sachs healthcare conference June 12 in Dana Point, Calif.